The BioPharm Brief: RNA Editing, Liver Safety, Joint Gains

Episode 4  ·  May 20, 08:50 PM
Headliner
Share
Subscribe

New clinical trial updates highlight advances in RNA editing for alpha-1 antitrypsin deficiency, semaglutide data in MASH liver disease, and improved joint outcomes in psoriatic arthritis treatment comparisons.

Share
Subscribe
Next
The BioPharm Brief: Smarter Platforms, Safer Therapies, AI Acceleration
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief